Michael Kavur, DO
Psychiatry · Estill Springs, TNNPI 1891140919
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,246 of the $44,266 with a category attached, or 81.9%. Teva Pharmaceuticals USA, Inc. accounts for 91.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $41,506, more than ten times the $202 reported in 2022. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $172.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$41K
- Neurocrine Biosciences, Inc.$742
- AbbVie$507
- Alkermes, Inc.$469
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$438
- Vanda Pharmaceuticals Inc.$404
- plus $1K from 7 others
What the payments were for
- Consulting fees$4601%
- Speaking & faculty fees$36,24682%
- Travel & lodging$2,3015%
- Food & beverage$5,04511%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 78 | $40,537 |
| Neurocrine Biosciences, Inc. | 30 | $742 |
| AbbVie | 26 | $507 |
| Alkermes, Inc. | 24 | $469 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $438 |
| Vanda Pharmaceuticals Inc. | 16 | $404 |
| Johnson & Johnson(2 entities) | 17 | $311 |
| Axsome Therapeutics, Inc. | 8 | $277 |
| E.r. Squibb & Sons, L.L.C. | 11 | $219 |
| Otsuka America Pharmaceutical, Inc. | 9 | $185 |
| Lundbeck LLC | 5 | $134 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$39,108
- Auvelity$124
- VRAYLAR$123
How this compares
$44,266 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $162,755 |
| VraylarCariprazine Hcl | 31 | $58,025 |
| CaplytaLumateperone Tosylate | 20 | $37,869 |
| Invega SustennaPaliperidone Palmitate | 11 | $36,021 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $34,201 |
| Clozapine | 79 | $9,887 |
| BelsomraSuvorexant | 12 | $5,021 |
| Haloperidol | 39 | $2,945 |
| Aripiprazole | 34 | $2,384 |
| Varenicline Tartrate | 12 | $1,834 |
| Hydroxyzine Hcl | 49 | $1,404 |
| Divalproex Sodium | 33 | $1,359 |
| Bupropion XlBupropion Hcl | 51 | $1,105 |
| Buspirone Hcl | 56 | $1,093 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 41 | $901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $742 | $162,75522 claims |
| AbbVieVraylar | $507 | $58,02531 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $438 | $37,86920 claims |
| Johnson & JohnsonInvega Sustenna | $311 | $36,02111 claims |
| Alkermes, Inc.Lybalvi | $469 | $34,20121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Estill Springs
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Sricharan MoturiFranklin$82K
- Michelle CochranNashville$74K
- Daniel BoydMemphis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.